SG11202013231SA - HIGH-AFFINITY, ISOFORM-SELECTIVE TGFß1 INHIBITORS AND USE THEREOF - Google Patents

HIGH-AFFINITY, ISOFORM-SELECTIVE TGFß1 INHIBITORS AND USE THEREOF

Info

Publication number
SG11202013231SA
SG11202013231SA SG11202013231SA SG11202013231SA SG11202013231SA SG 11202013231S A SG11202013231S A SG 11202013231SA SG 11202013231S A SG11202013231S A SG 11202013231SA SG 11202013231S A SG11202013231S A SG 11202013231SA SG 11202013231S A SG11202013231S A SG 11202013231SA
Authority
SG
Singapore
Prior art keywords
tgfß1
isoform
affinity
inhibitors
selective
Prior art date
Application number
SG11202013231SA
Inventor
Abhishek Datta
Allan Capili
Thomas Schurpf
Constance Martin
Kevin Dagbay
Christopher Chapron
Stefan Wawersik
Christopher Littlefield
Gregory Carven
Alan Buckler
Susan Lin
Justin Jackson
Caitlin Stein
Andrew Avery
Anthony Cooper
Matthew Salotto
Original Assignee
Scholar Rock Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scholar Rock Inc filed Critical Scholar Rock Inc
Publication of SG11202013231SA publication Critical patent/SG11202013231SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18211—Henipavirus, e.g. hendra virus
    • C12N2760/18234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11202013231SA 2018-07-11 2019-07-11 HIGH-AFFINITY, ISOFORM-SELECTIVE TGFß1 INHIBITORS AND USE THEREOF SG11202013231SA (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862696752P 2018-07-11 2018-07-11
US201862718196P 2018-08-13 2018-08-13
US201862737534P 2018-09-27 2018-09-27
US201862758180P 2018-11-09 2018-11-09
US201962810263P 2019-02-25 2019-02-25
US201962827552P 2019-04-01 2019-04-01
PCT/US2019/041373 WO2020014460A1 (en) 2018-07-11 2019-07-11 HIGH-AFFINITY, ISOFORM-SELECTIVE TGFβ1 INHIBITORS AND USE THEREOF

Publications (1)

Publication Number Publication Date
SG11202013231SA true SG11202013231SA (en) 2021-01-28

Family

ID=67470735

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202013231SA SG11202013231SA (en) 2018-07-11 2019-07-11 HIGH-AFFINITY, ISOFORM-SELECTIVE TGFß1 INHIBITORS AND USE THEREOF

Country Status (17)

Country Link
US (1) US20210122814A1 (en)
EP (1) EP3820508A1 (en)
JP (1) JP2021531254A (en)
KR (1) KR20210058811A (en)
CN (1) CN112996535A (en)
AU (1) AU2019302679A1 (en)
BR (1) BR112021000353A2 (en)
CA (1) CA3105988A1 (en)
CL (1) CL2021000073A1 (en)
CO (1) CO2021000419A2 (en)
IL (1) IL279914A (en)
MA (1) MA53125A (en)
MX (1) MX2021000347A (en)
PH (1) PH12021550020A1 (en)
SG (1) SG11202013231SA (en)
TW (1) TW202005981A (en)
WO (1) WO2020014460A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020014489A2 (en) 2018-07-11 2020-01-16 H. Lee Moffitt Cancer Center And Research Institute, Inc. Dimeric immuno-modulatory compounds against cereblon-based mechanisms
HUE056501T2 (en) 2018-07-11 2022-02-28 Scholar Rock Inc Isoform selective tgfbeta1 inhibitors and use thereof
WO2020160291A2 (en) 2019-01-30 2020-08-06 Scholar Rock, Inc. LTBP COMPLEX-SPECIFIC INHIBITORS OF TGFβ AND USES THEREOF
PE20221447A1 (en) 2019-08-28 2022-09-21 Chugai Pharmaceutical Co Ltd LATENT ANTI-TGF-BETA 1 ANTIBODIES AND METHODS OF USE
AU2021205440A1 (en) 2020-01-11 2022-09-01 Scholar Rock,Inc. TGF-beta inhibitors and use thereof
CA3167427A1 (en) 2020-01-11 2021-07-15 Scholar Rock, Inc. Tgfb inhibitors and use thereof
TW202140568A (en) * 2020-03-19 2021-11-01 日商中外製藥股份有限公司 Biomarkers for predicting the response to checkpoint inhibitors
WO2022204581A2 (en) 2021-03-26 2022-09-29 Scholar Rock, Inc. Tgf-beta inhibitors and use thereof
WO2022256723A2 (en) 2021-06-03 2022-12-08 Scholar Rock, Inc. Tgf-beta inhibitors and therapeutic use thereof
WO2022266510A1 (en) * 2021-06-18 2022-12-22 Genzyme Corporation Anti-tgf-beta antibody formulations and their use
WO2023288277A1 (en) 2021-07-14 2023-01-19 Scholar Rock, Inc. Ltbp complex-specific inhibitors of tgfb1 and uses thereof
CN113604214B (en) * 2021-08-09 2023-07-14 青岛大学 High-stability oncolytic peptide fluorescent probe and preparation method and application thereof
CN114236137A (en) * 2021-12-17 2022-03-25 中山大学·深圳 In-vitro detection kit for transforming growth factor beta and application thereof
CN115058440B (en) * 2022-06-08 2023-08-15 郑州轻工业大学 Engineering bacterium for catalyzing and synthesizing natural sucrose ester as well as construction method and application thereof

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
JPS6147500A (en) 1984-08-15 1986-03-07 Res Dev Corp Of Japan Chimera monoclonal antibody and its preparation
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
WO1990002809A1 (en) 1988-09-02 1990-03-22 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
CA2109602C (en) 1990-07-10 2002-10-01 Gregory P. Winter Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP0564531B1 (en) 1990-12-03 1998-03-25 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
JP4146512B2 (en) 1991-03-01 2008-09-10 ダイアックス コープ． Small protein
DK1471142T3 (en) 1991-04-10 2009-03-09 Scripps Research Inst Heterodimeric receptor libraries using phagemids
DE4122599C2 (en) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid for screening antibodies
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
NZ331688A (en) 1996-03-28 2000-02-28 Univ Johns Hopkins Soluble divalent and multivalent heterodimeric analogs of proteins
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US6492497B1 (en) 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
EP2042518A3 (en) 2000-06-29 2009-04-08 Abbott Laboratories Dual specificity antibodies and methods of making and using
EP1674480A4 (en) 2003-09-04 2007-06-20 Riken Antibody recognizing tgf-beta activation controlling region section
TR201901929T4 (en) 2005-02-08 2019-03-21 Genzyme Corp Antibodies to TGFBeta.
PE20091163A1 (en) 2007-11-01 2009-08-09 Wyeth Corp ANTIBODIES FOR GDF8
US20100260668A1 (en) 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
US9109026B2 (en) 2008-06-03 2015-08-18 Abbvie, Inc. Dual variable domain immunoglobulins and uses thereof
UY33421A (en) 2010-06-03 2011-12-30 Glaxo Wellcome House HUMANIZED ANTIGEN UNION PROTEINS
LT2780368T (en) 2011-11-14 2018-03-12 Regeneron Pharmaceuticals, Inc. Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing gdf8 and/or activin a
EP2971048B1 (en) * 2013-03-11 2018-10-31 Genzyme Corporation Engineered anti-tgf-beta antibodies and antigen-binding fragments
EP3816625A1 (en) * 2013-05-06 2021-05-05 Scholar Rock, Inc. Compositions and methods for growth factor modulation
EP3215175A4 (en) 2014-11-06 2018-06-27 Scholar Rock, Inc. Anti-pro/latent-myostatin antibodies and uses thereof
EP3307772B1 (en) 2015-06-12 2020-09-09 Ludwig Institute For Cancer Research Limited Tgf-beta 3 specific antibodies and methods and uses thereof
WO2017015622A2 (en) 2015-07-22 2017-01-26 Scholar Rock, Inc Gdf11 binding proteins and uses thereof
IL305148A (en) 2015-09-15 2023-10-01 Scholar Rock Inc Anti-pro/latent-myostatin antibodies and uses thereof
KR20180122397A (en) * 2016-03-11 2018-11-12 스칼러 락, 인크. TGFβ1-linked immunoglobulins and uses thereof
EP3551658A1 (en) 2017-01-06 2019-10-16 Scholar Rock, Inc. Isoform-specific, context-permissive tgf 1 inhibitors and use thereof
US20200231682A1 (en) 2017-07-28 2020-07-23 Scholar Rock, Inc. Ltbp complex-specific inhibitors of tgf-beta 1 and uses thereof

Also Published As

Publication number Publication date
JP2021531254A (en) 2021-11-18
CN112996535A (en) 2021-06-18
WO2020014460A1 (en) 2020-01-16
MA53125A (en) 2021-05-19
CA3105988A1 (en) 2020-01-16
CO2021000419A2 (en) 2021-01-29
MX2021000347A (en) 2021-04-19
AU2019302679A1 (en) 2021-02-11
TW202005981A (en) 2020-02-01
BR112021000353A2 (en) 2021-08-03
WO2020014460A8 (en) 2020-02-13
CL2021000073A1 (en) 2021-07-30
KR20210058811A (en) 2021-05-24
PH12021550020A1 (en) 2021-09-13
EP3820508A1 (en) 2021-05-19
IL279914A (en) 2021-03-01
US20210122814A1 (en) 2021-04-29

Similar Documents

Publication Publication Date Title
SG11202013231SA (en) HIGH-AFFINITY, ISOFORM-SELECTIVE TGFß1 INHIBITORS AND USE THEREOF
IL282487A (en) Tyk2 inhibitors and uses thereof
IL276095B1 (en) Gcn2 inhibitors and uses thereof
IL276147A (en) Gcn2 inhibitors and uses thereof
HK1258764A1 (en) Janus kinases inhibitors, compositions thereof and use thereof
EP3572400C0 (en) Ezh2 inhibitor and use thereof
IL282090A (en) Tyk2 inhibitors and uses thereof
IL283409A (en) Tyk2 inhibitors and uses thereof
IL282350A (en) Rgmc-selective inhibitors and use thereof
PT3621694T (en) Lrrc33 inhibitors and use thereof
IL284514A (en) Halo-allylamine compounds and use thereof
IL278701A (en) Heterocondensed pyridones compounds and their use as idh inhibitors
IL282939A (en) Mixtures and compositions comprising 5-fluoro-4-imino-3- methyl-1-tosyl-3,4- dihydropyrimidin-2-one, and methods of use thereof
SG11202011227VA (en) Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds and methods of use thereof
GB201909486D0 (en) Compositons, uses and methods
IL292198A (en) Tim-3 inhibitors and uses thereof
IL282527A (en) Azaindazole-5 derivatives and their use
EP3327021A4 (en) Janus kinase 1 selective inhibitor and pharmaceutical use thereof
IL282526A (en) Azaindazole-5 derivatives and their use
EP3596082A4 (en) Cdpk1 inhibitors, compositions and methods related thereto
EP3668875A4 (en) Cdpk1 inhibitors, compositions, and methods related thereto
GB201802122D0 (en) Product and use
EP3568128A4 (en) Hsp90b n-terminal isoform-selective inhibitors
ZA202104192B (en) Mmpl3 inhibitors, compositions and uses thereof
EP3474855A4 (en) Ck2 inhibitors, compositions and methods thereof